跳至主要内容
临床试验/NCT00165815
NCT00165815已完成3 期

The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia

Eisai Limited4 个研究点 分布在 2 个国家开始时间: 2002年8月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Eisai Limited
试验地点
4
主要终点
PD patients with dementia will be screened up to 4 weeks prior to initiating dose administration. Baseline measurement on efficacy measures will be conducted at baseline, after which the first dose of study medication will be administered.

研究概览

简要总结

A randomised, double-blind, 3-arm parallel group study comparing Aricept® with placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients with an established diagnosis of PD and dementia, who fulfill all of the inclusion criteria and none of the

排除标准

  • •listed below, will be eligible for enrolment into this study.
  • •Best efforts must be made on clinical grounds to exclude patients with DLB and AD. The key inclusion criteria in this respect is the onset of dementia documented to have occurred at least 1 year after the diagnosis of PD.

结局指标

主要结局

PD patients with dementia will be screened up to 4 weeks prior to initiating dose administration. Baseline measurement on efficacy measures will be conducted at baseline, after which the first dose of study medication will be administered.

次要结局

未报告次要终点

研究者

发起方
Eisai Limited
申办方类型
Industry

研究点 (4)

Loading locations...

相似试验